Search Results 491-500 of 17431 for alopecia
recovered from adverse events (other than alopecia or neuropathy) due to agents administered more than 4 weeks earlier. However, the following therapies are ...
Recovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy (excluding alopecia) prior to initiation of study drug ...
... alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment. Radiation therapy administered within 2 weeks ...
... alopecia -Receiving any other investigational agents =< 28 days prior to registration -Known brain metastases (even if treated) -Known portal hypertension ...
* Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.
It is part of the body's system of glands that make hormones, called the endocrine system. The pituitary gland makes several hormones. They act on nearly every ...
The patient must have recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non ...
Participants with diabetes Type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
Lichen sclerosus, Lichen planus, Skin wrinkles, Vulvar disorder, Acne, Alopecia areata, Melasma, Age spots, UV skin damage, Rosacea, Canker sores, Actinic ...
... alopecia, anemia and any signs or symptoms of androgen deprivation therapy; Must be willing to not add, delete or change their current bisphosphonate or ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.